{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:26:03Z","timestamp":1773275163923,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":1467,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1038\/mt.2012.133","type":"journal-article","created":{"date-parts":[[2012,8,7]],"date-time":"2012-08-07T12:34:48Z","timestamp":1344342888000},"page":"1924-1931","source":"Crossref","is-referenced-by-count":16,"title":["Administration of Anti-CD3 Antibodies Modulates the Immune Response to an Infusion of \u03b1-glucosidase in Mice"],"prefix":"10.1016","volume":"20","author":[{"given":"Toya","family":"Ohashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayoko","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohta","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikatsu","family":"Eto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Ida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2012.133_bib1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1038\/mt.2012.133_bib2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"10.1038\/mt.2012.133_bib3","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2012.133_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","article-title":"Enzyme replacement therapy in the mouse model of Pompe disease","volume":"80","author":"Raben","year":"2003","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2012.133_bib5","first-page":"132","article-title":"Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet Med"},{"key":"10.1038\/mt.2012.133_bib6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","article-title":"Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease","volume":"149","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"10.1038\/mt.2012.133_bib7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2012.133_bib8","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","article-title":"High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa","volume":"101","author":"de Vries","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2012.133_bib9","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet Med"},{"key":"10.1038\/mt.2012.133_bib10","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2249.2008.03602.x","article-title":"Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model","volume":"152","author":"Joseph","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1038\/mt.2012.133_bib11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJMc0806809","article-title":"Elimination of antibodies to recombinant enzyme in Pompe's disease","volume":"360","author":"Mendelsohn","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2012.133_bib12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet Med"},{"key":"10.1038\/mt.2012.133_bib13","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s10545-010-9209-0","article-title":"CRIM-negative infantile Pompe disease: 42-month treatment outcome","volume":"33","author":"Rohrbach","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/mt.2012.133_bib14","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/mt.2010.164","article-title":"Induction of immune tolerance to a therapeutic protein by intrathymic gene delivery","volume":"18","author":"Chu","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2012.133_bib15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/jgm.1305","article-title":"Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease","volume":"11","author":"Douillard-Guilloux","year":"2009","journal-title":"J Gene Med"},{"key":"10.1038\/mt.2012.133_bib16","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1182\/blood-2009-11-252874","article-title":"Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype","volume":"115","author":"van Til","year":"2010","journal-title":"Blood"},{"key":"10.1038\/mt.2012.133_bib17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2011.01.009","article-title":"Oral administration of recombinant human acid a-glucosidase reduces specific antibody formation against enzyme in mouse","volume":"103","author":"Ohashi","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2012.133_bib18","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/522236","article-title":"Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance","volume":"81","author":"Sun","year":"2007","journal-title":"Am J Hum Genet"},{"key":"10.1038\/mt.2012.133_bib19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/mt.2009.195","article-title":"Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease","volume":"18","author":"Sun","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2012.133_bib20","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/jgm.1511","article-title":"Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease","volume":"12","author":"Sun","year":"2010","journal-title":"J Gene Med"},{"key":"10.1038\/mt.2012.133_bib21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2009.07.001","article-title":"Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa","volume":"98","author":"Lipinski","year":"2009","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2012.133_bib22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1182\/blood-2008-04-151597","article-title":"Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response","volume":"113","author":"Waters","year":"2009","journal-title":"Blood"},{"key":"10.1038\/mt.2012.133_bib23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ymgme.2008.03.008","article-title":"Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease","volume":"94","author":"Ohashi","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2012.133_bib24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2007.06.013","article-title":"Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy","volume":"92","author":"Ohashi","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2012.133_bib25","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/nm924","article-title":"TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes","volume":"9","author":"Belghith","year":"2003","journal-title":"Nat Med"},{"key":"10.1038\/mt.2012.133_bib26","doi-asserted-by":"crossref","first-page":"6335","DOI":"10.1073\/pnas.0701171104","article-title":"Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment","volume":"104","author":"You","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2012.133_bib27","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/mus.22136","article-title":"Enzyme replacement therapy induces T-cell responses in late-onset Pompe disease","volume":"44","author":"Banati","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1038\/mt.2012.133_bib28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(11)60931-8","article-title":"Teplizumab for treatment of type 1 diabetes (Prot\u00e9g\u00e9 study): 1-year results from a randomised, placebo-controlled trial","volume":"378","author":"Sherry","year":"2011","journal-title":"Lancet"},{"key":"10.1038\/mt.2012.133_bib29","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/ibd.21084","article-title":"Prospective randomized open-label multicenter phase I\/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis","volume":"16","author":"Baumgart","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1038\/mt.2012.133_bib30","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/ibd.21252","article-title":"Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease","volume":"16","author":"van der Woude","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1038\/mt.2012.133_bib31","doi-asserted-by":"crossref","first-page":"68ra10","DOI":"10.1126\/scitranslmed.3001830","article-title":"Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance","volume":"3","author":"Kuhn","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1038\/mt.2012.133_bib32","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/gt.2009.160","article-title":"Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction","volume":"17","author":"Kyosen","year":"2010","journal-title":"Gene Ther"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500161632189X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500161632189X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T15:58:47Z","timestamp":1562083127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500161632189X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S152500161632189X"],"URL":"https:\/\/doi.org\/10.1038\/mt.2012.133","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}